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Endometrioid endometrial adenocarcinoma (EAC) and uterine serous carcinoma (USC) are distinct tumors with different molecular pathways, clinical behavior, and prognosis. 1, 2 Therefore, differentiating between these subtypes is of major clinical importance. EACs are the most frequent subtype and account for more than 80% of EAC cases. They are associated with obesity and exogenous hormonal therapy. EACs have a relatively good cure rate, with a 5-year survival rate of 80% to 90% in stage I disease. Morphologically, EACs are characterized by glandular architecture with 3 grades of differentiation (G1, G2, and G3). On the other hand, patients with USC stage I disease have a 5-year survival rate of 60%. These tumors are usually characterized by papillary architecture and are always considered high-grade (G3) tumors. [1] [2] [3] [4] [5] [6] Although differentiating between EAC and USC is usually easily accomplished, there are multiple variations that we should consider. For example, not all USCs have papillary architecture because they may manifest in glandular or tubuloglandular patterns. Similarly, EAC could manifest with papillary architecture. Finally, high-grade EACs may manifest as solid sheets of tumor cells, and differentiating them from USC can be very difficult. 7 This confusion is more frequent for pathologists with limited experience in gynecologic pathology who might be unaware of these morphologic variations.
To address this issue, many immunomarkers have previously been evaluated to distinguish EAC from USC. However, we decided to evaluate 4 antibodies, including β-catenin, p53, PTEN, and, most recently, IMP3 for our study, and mainly because of their proven value in previous published studies. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] β-catenin belongs to the E-cadherin/β-catenin complex and has an important role in the maintenance of epithelial cell-cell adhesion. 10 Also, β-catenin acts as an oncogene via its Upon completion of this activity you will be able to:
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activation of the wingless-Wnt signaling pathway. 11 Although membranous accumulation of β-catenin can be seen in normal epithelium, its accumulation in the cytoplasm and/or nucleus is considered abnormal. Nuclear staining of β-catenin can be present in high-grade EAC and is uncommonly seen in USC. 12, 13 A p53 mutation is an early event in carcinogenesis and is an important pathway in the pathogenesis of USC. Overexpression of p53 as shown by immunohistochemical analysis has been detected in 80% to 100% of USC cases and in 10% to 30% of EACs, with most of these cases being highgrade tumors. [14] [15] [16] PTEN (phosphate tensin homolog) is a tumor suppressor gene located at chromosome 10q23. Mutations of the PTEN gene have been seen in 30% to 60% of endometrial carcinomas, most frequently in the endometrioid subtype. [17] [18] [19] [20] IMP3, an insulin-like growth factor II messenger RNAbinding protein 3 (IMP3), is an oncofetal protein that is highly expressed in fetal tissue. 21 It has been implicated in tumor growth, migration, and invasion. IMP3 was found to be immunoexpressed in 94% to 100% of USCs and in 7% to 25% of EAC cases. 22, 23 In this study, we examined a series of EAC and USC cases for β-catenin, PTEN, p53, and IMP3 expression by immunohistochemical analysis. We first evaluated a total of 103 cases, 88 cases of pure EAC and pure USC, including 17 challenging and problematic cases. We then applied these results to 15 cases of mixed endometrioid adenocarcinoma and serous carcinoma (mixed EAC-USC). The goals of this study were to identify the value of any single marker or any combination of markers in differentiating pure EAC from pure USC, even when encountering challenging cases, and to determine whether the markers are helpful in diagnosing the serous component in mixed EAC-USC tumors.
Materials and Methods

Case Selection and Histologic Review
Hysterectomy specimens from EAC cases were retrieved from the archives of the Department of Surgical Pathology, Roswell Park Cancer Institute, Buffalo, NY. This was a retrospective and selective study in which different tumor grades, subtypes (endometrioid and serous), and mixed EAC-USC tumor types were included. We performed this study under a protocol approved by the Roswell Park Cancer Institute Institutional Review Board. All cases were reviewed by 2 pathologists (P.M.-F. and H.R.) to confirm the histologic subtypes and tumor grading.
All EAC cases were graded based on the most recent revision of the International Federation of Gynecology and Obstetrics (FIGO) architectural grading system and the World Health Organization histopathologic classification that recommend that tumors be graded using both architectural and nuclear criteria. 24, 25 All USCs are, by definition, grade 3 tumors. A total of 88 cases of pure EAC and pure USC and 15 cases of mixed EAC-USC were selected for evaluation. By morphologic examination, 57 cases were classified as pure EAC.
The challenging EAC and USC cases mainly had discordance between architectural pattern and nuclear grade. In 9 of 57 EAC cases, the diagnosis was difficult because the tumor had papillary architecture, an eosinophilic syncytial pattern, and eosinophilic with hobnail changes that can be mistaken for USC ❚Image 1❚. The histologic features that we used to classify them as EACs were cells with low nuclear grade and inconspicuous nucleoli. The large, rounded, bizarre nuclei with prominent eosinophilic nucleoli as seen in serous carcinoma should be missing. In addition, 2 of 9 cases were associated with atypical endometrial hyperplasia. As for follow-up data, 8 of 9 cases had no recurrence, and 1 had progression of disease. Of the 9 patients, 8 were alive with no evidence of disease and 1 was alive with disease.
Of 31 cases of pure USC, 8 cases were diagnostically challenging cases because they had glandular architecture that can be a pitfall in the differential diagnosis with EAC ❚Image 2❚. The histologic features that we used to classify these as USC were discordance between a predominantly glandular architecture associated with high cytologic nuclear grade as defined by bizarre nuclear forms and prominent nucleoli. Of the 8 cases, 6 were associated with in situ serous carcinoma as precursors.
As for follow-up, 3 of 8 patients had recurrence of disease, with a biopsy confirming a serous carcinoma in the recurrent site, and 5 had no recurrence. Of the 8 patients, 3 had died of disease, 2 were alive with disease, and 3 were alive with no evidence of disease. The aforementioned diagnostically challenging cases were sent from an outside facility and/ or by nongynecologist-pathologists within our department for consultation or a second opinion.
In addition, 15 cases were mixed EAC-USC, and the percentage of serous component in these cases ranged from 10% to 40%. In those tumors, the diagnosis was straightforward when we could evaluate the existence of a classic endometrioid adenocarcinoma, FIGO stage I and low nuclear grade (grade 1), associated with a classic serous carcinoma with a papillary pattern and high nuclear grade. These 2 components were seen in the same section or in different sections. The serous component varied from 10% to 40% of the tumor volume, depending on the case. Although 25% or more of the serous component would behave as serous carcinoma, recent reports have suggested that as little as 10% of the serous component, or even less, could be considered as indicating a poor prognosis. 26 Thus, in our institute, the diagnosis would always be mixed epithelial tumor with citation of the percentage of each component.
Immunohistochemical Analysis
For immunohistochemical analysis, 4-μm whole sections from formalin-fixed, paraffin-embedded tissue samples were processed. Sections were cooled for 20 minutes and incubated 10 minutes with 3% hydrogen peroxide to quench endogenous peroxidase activity. Blocking was performed by using a serum-free protein block (DakoCytomation, Carpinteria, CA) for 30 minutes. Antibodies and conditions are summarized in ❚Table 1❚. We used the 6.H2.1 monoclonal antibody for PTEN because it was found to be the best immunomarker in comparison with other commercially available antibodies. 19 Diaminobenzidine tetrahydrochloride was then added for development for 10 minutes, followed by counterstaining with hematoxylin solution. Negative control slides omitting the primary antibody were included in all assays. A blind, semiquantitative evaluation of the immunohistochemical slides was performed by 2 pathologists (P.M.-F. and H.R.) at a double-headed microscope.
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❚Image 1❚ A, Low magnification of an endometrioid adenocarcinoma case resembling uterine serous carcinoma (USC) in which the tumor shows eosinophilic changes with pseudopapillary architecture (H&E, ×10). B, However, higher magnification revealed that the cytoplasm is still very abundant and the nuclear/cytoplasmic ratio is maintained. In addition, the bizarre, round nuclei with prominent nucleoli that characterized USC are absent (H&E, ×40).
❚Image 2❚ A, Uterine serous carcinoma (USC) mimicking endometrioid adenocarcinoma (EAC). The tumor has a glandular architecture (H&E, ×10). B, Higher magnification revealed that the tumor cells lining these glands are hobnail cells showing marked nuclear atypia, prominent nucleoli, and numerous mitotic figures (H&E, ×40). The discordance between the glandular architecture and the nuclear grade should lead to a diagnosis of USC rather than EAC.
For each case and each marker, we evaluated percentages of positive tumor cells and staining intensity. Intensity was considered first; however, it was dropped later in the study because the distribution prevented application of logistic regression. Thus, we were left with the percentage of tumor cells as a parameter for analysis. Knowing that there is no consensus on the cutoff for positivity of these immunomarkers, we adopted the cutoff from a previous report 27 and validated them in our statistical model. We designated the cutoff values for positivity as follows: β-catenin, more than 0%; p53, more than 75%; PTEN, 10% or more; and IMP3, 5% or more. For β-catenin, only nuclear staining was considered positive. The staining pattern of IMP3, β-catenin, and PTEN was focal, and it was diffuse for p53 antibody.
Statistical Analysis
Comparisons between groups were performed by using the Fisher exact test for binary data and the Mann-Whitney U test for ordinal data. For each tested marker, receiver operating characteristic curves showing sensitivity and the false-positive rate (1 -specificity) over a range of possible threshold values were examined. The performance of each marker was evaluated by computing the area under the curve (AUC).
An ideal test would have an AUC of 1.0, whereas a useless test will have an AUC of 0.5 or less. A P value of less than .05 was considered statistically significant. Statistics were performed using Stata Statistical Software, release 10.1 (Stata, College Station, TX).
Results
The ages of the patients ranged from 30 to 93 years (mean, 65.6 years). The grading of the 57 pure EAC cases was as follows: G1, 12; G2, 27; and G3, 18. The 31 USC cases were G3. The FIGO staging of 88 cases was distributed as follows: I, 54; II, 12; III, 18; and IV, 4. The immunoexpression of the 4 markers in EAC and USC is summarized in ❚Table 2❚. β-catenin was more frequently expressed in EAC (P = .001). On the other hand, p53, PTEN, and IMP3 were more frequently detected in USC (P < .001 for each). ❚Table 3❚ shows the association of the expression of these markers with EAC tumor grade and stage where p53 expression was the only marker to be strongly associated with tumor grade (P = .0002), meaning that highgrade (G3) EAC showed p53 expression more frequently than did G1 and G2 tumors. Furthermore, all other markers, including β-catenin, PTEN, and IMP3, did not show any association with EAC tumor grade.
To evaluate the value of these markers in distinguishing USC from EAC, we performed univariate and multivariate exact logistic regression analysis ❚Table 4❚. ❚Figure 1❚ shows the receiver operating characteristic curve with IMP3 being the best marker for diagnosing USCs. This high predictive value of IMP3 was maintained even after we applied multivariate analysis and after adjusting for other variables such as tumor stage and grade. When using combinations of all 4 markers, the most reliable combination for predicting USC was PTEN+/ IMP3+ with an exact odds ratio of 163.87 (95% confidence interval, 19.62 to infinity; P < .001), and the second best combination of markers was p53+/IMP3+ with an exact odds ratio of 47.87 (95% confidence interval, 6.51 to infinity; P < .001).
The immunoexpression of the 4 markers in the 9 challenging EAC cases revealed that 1 case (11%) was positive for β-catenin, 2 (22%) were positive for p53, 0 (0%) were positive for IMP3, and 6 (67%) lacked PTEN expression. Meanwhile, of the 8 challenging USC cases, 0 (0%) were positive for β-catenin, 7 (88%) were positive for p53, 8 (100%) were positive for IMP3, and 1 (13%) lacked PTEN. One example of an EAC case and one of a USC case are illustrated in ❚Image 3❚ and ❚Image 4❚, respectively. IMP3+ expression is the best combination of markers to predict that a tumor is 163 times more likely to be a USC than an EAC. IMP3 is a newly identified oncoprotein that seems to be involved in embryogenesis and in carcinogenesis in malignant pancreatic, renal, and endocervical tumors. [28] [29] [30] There are 2 published studies discussing IMP3 expression in endometrial carcinoma, by Li et al 22 Last, when we applied these predictive markers in making a diagnosis of the serous component in mixed EAC-USC, these markers demonstrated no value. This was mainly for the focal staining pattern for IMP3, PTEN, and β-catenin. This pattern of immunoexpression created a major limitation in making a diagnosis of the serous component in mixed EAC-USC tumors.
Discussion
In this study, we showed that IMP3 is the most powerful immunomarker for distinguishing USC from EAC, even in challenging cases exhibiting architectural variations. Most important, and unlike p53, IMP3 expression is not affected by high EAC tumor grade. Furthermore, PTEN+/ of EACs were completely negative for IMP3. However, Li et al 22 discussed only the IMP3 antibody in USC, and Zheng et al 23 added p53 as a second marker. In addition, neither study evaluated the sensitivity or the predictive value of IMP3 or any of the combinations of these markers. These studies were observations on the staining pattern of expression for IMP3 in USC, EAC, and other premalignant lesions. However, both studies concluded that there was significant expression of IMP3 in USCs compared with EACs, which implies that IMP3 may be a useful diagnostic marker in EACs.
In our study, we addressed a diagnostic dilemma in which we further evaluated the predictive value of IMP3 in distinguishing USC from EAC, taking tumor grade into consideration. We found that IMP3 had the best predictive value for differentiating USCs from EACs, and, in contrast with p53, the predictive value was not affected by tumor grade. The p53 immunomarker has been widely used for USC diagnosis. However, p53 has a lack of specificity, as noted in numerous studies, including ours, being expressed in a high percentage of high-grade EACs. 14, 31 A decrease in PTEN expression has been described in EAC cases and was suggested to be a significant marker when differentiating EAC from USC. 19, 20 We did not find PTEN to be a reliable marker by itself. However, the PTEN+/IMP3+ pattern of expression seemed very reliable in predicting USC. The value of this combination was valid, independent of tumor grade and stage.
These markers were of little value in identifying the serous component in mixed EAC-USC tumors. This is mainly because of the staining pattern of these markers, which seemed to be focally expressed in the majority of cases. This fact made the interpretation of immunoexpression of these markers very limited and extremely difficult in mixed tumor types.
Our study is a novel strategy for addressing several important issues that may have a great impact on prognosis, treatment, and management. We concluded that IMP3 and PTEN+/IMP3+ patterns are very powerful markers for differentiating USC from EAC, especially in high-grade EAC. In addition, we strongly recommend that they be used in appropriate surgical pathology cases, such as the cases exhibiting a discrepancy between glandular pattern and degree of cytologic atypia. 
